Tag Archives: FDA

Dextera Surgical Inc (NASDAQ:DXTR) is up more than 120% so far this week, on a corporate update put out by management to address the fiscal 2017 sales of its lead asset. If the numbers outlined in the update can be hit, and based on the numbers...

Low floats have been the name of the game for a number of biotech companies this week, with some seemingly inexplicable runs only explained by low float, high-volume spikes. Here is another one. The company is GenVec Inc (NASDAQ:GNVC), and...

At the end of first quarter 2014, Immune Pharmaceuticals Inc (NASDAQ:IMNP) traded for just shy of $4.50 a share. During the 36 or so months since, the company has declined to trade at current levels below $0.2 a share – a more than 95% decline...

CEL-SCI Corporation (NYSEMKT:CVM) has had a noteworthy run year to date. The company started out 2017 at around $0.07 a share, and has since gained to trade above $0.11 – a 60% gain across the period. The gains, however, haven’t really...

22nd Century Group Inc (NYSEMKT:XXII) took a hit late last week on its latest release. The company put out an update regarding its lead product, a so called Very Low Nicotine cigarette (we’re capitalizing this because it’s a brand...

The end of the year is pretty much here, and we’re going to highlight Elite Pharmaceuticals Inc (OTCMKTS:ELTP) one last time. We’ve done so numerous times over the last couple of quarters, pointing out the company’s potential...

Neovasc Inc (US) (NASDAQ:NVCN) has had a big close to the year. The company entered December at around $.5 a share. By December 6, this had risen to more than $3.20 a share. At most recent close, the company went for $1.70 – a 22% gain on...

Pharmacyte Biotech Inc (OTCMKTS:PMCB) just put out a press release detailing some research conducted in Chicago, and the company has picked up an 11% boost on the release. The research doesn’t relate directly to PharmaCyte, but it does...

Achaogen Inc (NASDAQ:AKAO) is running up on the back of some phase III data, currently trading at a close to 380% premium to its last week price. The data relates to an antibiotic called plazomicin – the company’s lead asset in this...

Anavex Life Sciences Corp. (NASDAQ:AVXL) is picking up strength on the back of a corporate update, which offered a high degree of clarity in to the company’s numbers and operations ahead of what looks set to be a pivotal 2017 for the...

Sign Up Now For Our FREE Small Cap Newsletter

Sign Up Now For Our FREE Small Cap Newsletter

Sign Up Now For Our FREE Small Cap Newsletter

Sign Up Now For Our FREE Small Cap Newsletter

Sign Up Now For Our FREE Small Cap Newsletter

Sign Up Now For Our FREE Small Cap Newsletter

Sign Up Now For Our FREE Small Cap Newsletter

Sign Up Now For Our FREE Small Cap Newsletter

Sign Up Now For Our FREE Small Cap Newsletter

Sign Up Now For Our FREE Small Cap Newsletter